These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 11361210)

  • 21. Spontaneously reported fatal suspected adverse drug reactions: a 10-year survey from Sweden.
    Wester K; Jönsson A; Spigset O; Hägg S
    Pharmacoepidemiol Drug Saf; 2007 Feb; 16(2):173-80. PubMed ID: 16739241
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of databases in drug postmarketing surveillance.
    Rodriguez EM; Staffa JA; Graham DJ
    Pharmacoepidemiol Drug Saf; 2001; 10(5):407-10. PubMed ID: 11802586
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Automated support for pharmacovigilance: a proposed system.
    Bright RA; Nelson RC
    Pharmacoepidemiol Drug Saf; 2002 Mar; 11(2):121-5. PubMed ID: 11998536
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [French system of drug surveillance].
    Imbs JL; Castot A; Begaud B; Larousse C; Blayac JP; Alexandre JM
    Bull Acad Natl Med; 1998; 182(7):1383-91; discussion 1392-3. PubMed ID: 9916332
    [TBL] [Abstract][Full Text] [Related]  

  • 25. From the Uppsala monitoring centre: a review of viewpoint part 1 and part 2.
    Hugman B
    Drug Saf; 2005; 28(7):645-6. PubMed ID: 15963009
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A pilot study to build a database on seven anti-hypertensive drugs.
    Fujita T; Miura Y; Mayama T
    Pharmacoepidemiol Drug Saf; 2005 Jan; 14(1):41-6. PubMed ID: 15534857
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patient reporting of suspected adverse drug reactions: a review of published literature and international experience.
    Blenkinsopp A; Wilkie P; Wang M; Routledge PA
    Br J Clin Pharmacol; 2007 Feb; 63(2):148-56. PubMed ID: 17274788
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of the WHO programme on International Drug Monitoring in coordinating worldwide drug safety efforts.
    Olsson S
    Drug Saf; 1998 Jul; 19(1):1-10. PubMed ID: 9673854
    [TBL] [Abstract][Full Text] [Related]  

  • 29. National differences in reporting 'pneumonia' and 'pneumonia interstitial': an analysis of the WHO International Drug Monitoring Database on 15 drugs in nine countries for seven pulmonary conditions.
    Koo LC; Clark JA; Quesenberry CP; Higenbottam T; Nyberg F; Wolf MK; Steinberg MH; Forsythe BH
    Pharmacoepidemiol Drug Saf; 2005 Nov; 14(11):775-87. PubMed ID: 15654720
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The nature of the scientific evidence leading to drug withdrawals for pharmacovigilance reasons in France.
    Olivier P; Montastruc JL
    Pharmacoepidemiol Drug Saf; 2006 Nov; 15(11):808-12. PubMed ID: 16700082
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Standardizing assessment of adverse effects in rheumatology clinical trials. Status of OMERACT Toxicity Working Group March 2000: towards a common understanding of comparative toxicity/safety profiles for antirheumatic therapies.
    Woodworth TG; Furst DE; Strand V; Kempeni J; Fenner H; Lau CS; Miller F; Day R; Lipani J; Brooks P
    J Rheumatol; 2001 May; 28(5):1163-9. PubMed ID: 11361207
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation and overview of the National Electronic Injury Surveillance System-Cooperative Adverse Drug Event Surveillance Project (NEISS-CADES).
    Jhung MA; Budnitz DS; Mendelsohn AB; Weidenbach KN; Nelson TD; Pollock DA
    Med Care; 2007 Oct; 45(10 Supl 2):S96-102. PubMed ID: 17909391
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adverse reaction assessment in Thailand.
    Sriwatanakul K; Pothisiri P
    Med Toxicol; 1986; 1 Suppl 1():105-9. PubMed ID: 3821423
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Computerization and the importance of information in health system, as in health care resources registry].
    Troselj M; Fanton D
    Acta Med Croatica; 2005; 59(3):251-7. PubMed ID: 16095200
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Surveillance system for adverse events following immunization against yellow fever in Burkina Faso in 2008. Good practice recommendations].
    Yaméogo TM; Breugelmans JG; Kambou JL; Badolo O; Tiendrebéogo S; Traoré E; Avokey F; Yactayo S
    Med Trop (Mars); 2009 Aug; 69(4):320-1. PubMed ID: 19725376
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessing the impact of drug safety signals from the WHO database presented in 'SIGNAL': results from a questionnaire of National pharmacovigilance Centres.
    Ståhl M; Edwards IR; Bowring G; Kiuru A; Lindquist M
    Drug Saf; 2003; 26(10):721-7. PubMed ID: 12862506
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept.
    Feltelius N; Fored CM; Blomqvist P; Bertilsson L; Geborek P; Jacobsson LT; Lindblad S; Lysholm J; Rantapää-Dahlqvist S; Saxne T; Klareskog L;
    Ann Rheum Dis; 2005 Feb; 64(2):246-52. PubMed ID: 15208177
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparison of measures of disproportionality for signal detection on adverse drug reaction spontaneous reporting database of Guangdong province in China.
    Li C; Xia J; Deng J; Jiang J
    Pharmacoepidemiol Drug Saf; 2008 Jun; 17(6):593-600. PubMed ID: 18432629
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Drug monitoring in Tunisia: organization and objectives].
    Daghfous R; Elaidi S; Loueslati MH; Srairi S; Lakhal M; Belkahia C
    Tunis Med; 1994 Feb; 72(2):83-6. PubMed ID: 7974826
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.